Browse
Submit Data
Databases
API
Help

Dataset Information

16 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Open, randomized, controlled, multicenter phase II study comparing 5-FU/FA plus oxaliplatin (FOLFOX 4) plus cetuximab versus 5-FU/FA plus oxaliplatin as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer

ABSTRACT: Primary objectives: To assess whether the rate of best confirmed response of 5-FU/FA plus oxaliplatin plus cetuximab is superior to 5-FU/FA plus oxaliplatin as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer. Primary endpoints: Best confirmed response

DISEASE(S): Metastatic Colon Rectal Carcinoma

PROVIDER: 2517174 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Open, randomized, controlled, multicenter phase III study comparing 5-FU/FA plus irinotecan plus cetuximab versus 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer.

Project description:Primary objectives: To assess whether the progression-free survival time under 5-FU/FA plus irinotecan plus cetuximab is longer than that under 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer. Primary endpoints: Progression free survival

| 2515383 | ecrin-mdr-crc

OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRCOpen, non-controlled, multicenter phase II study evaluating 5-FU/FA plus oxaliplatin (FOLFOX-4) plus cetuximab as first-line treatment for patients with undetectable EGFR-status in metastatic colorectal cancer.

Project description:Primary objectives: To assess the rate of best confirmed response of 5-FU/FA plus oxaliplatin plus cetuximab as first-line treatment for undetectable epidermal growth factor in metastatic colorectal cancer. Primary endpoints: The primary target variable related to efficacy is the best overall confirmed tumor response to therapy of either CR or PR . Secondary target variables related to efficacy comprise variables based on tumor response and survival time. The following variables describe those, which are directly related to tumor response: • The duration of response to assess the time from first assessment of CR or PR until the first date of PD or death• Disease control on therapy, i.e. best overall response is either CR, PR, SD, provided the confirmation criteria are met (see section 7.2.3) • Progression-free survival time of a patient being defined as the time in months from start of treatment until PD is observed or death occurs due to any cause within 90 days after the last tumor assessment. In addition, survival time and curative metastatic surgery will be of further interest.

| 2518616 | ecrin-mdr-crc

High-throughput sequencing analysis of miRNAs expression profiles in the HCT116 colorectal cancer sublines resistant to oxaliplatin (Oxa) or 5-fluorouracil (5-FU).

Project description:In the present study, we investigated miRNA expression changes caused by aquired chemoresistance to 5-FU or Oxa. 40 and 14 miRNAs were detected as differentially expressed in 5-fluouracil- and oxaliplatin-resistant colorectal HCT116 sublines, respectively. Differentially expressed miRNAs determined in the present study could be applied for further development of diagnostic and therapeutic applications for colorectal cancer carcinoma resistant to 5-FU or Oxa.

2019-12-31 | GSE119481 | GEO

Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer

Project description:To see if Disease Free Survival (DFS) is improved when complete surgical resection of liver metastases (R0) is followed by chemotherapy with CPT-11 and 5-FU/FA as FOLFIRI regimen, compared to 5-FU/FA alone.

| 2015253 | ecrin-mdr-crc

Pre-treatment metastatic biopsy with response to 5FU and oxaliplatin therapy

Project description:Pre-treatment metastatic (liver) biopsies were harvested prior to 5-FU and oxaliplatin therapy. CT imaging for response evaluation using WHO criteria was performed every 6 weeks.

2011-10-31 | E-MEXP-3368 | biostudies-arrayexpress

Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer

Project description:The purpose of this study is to assess a maximal tolerable dose and to assess the safety of a chemotherapy-combination of cetuximab, irinotecan, oxaliplatin and 5-fluorouracil (5-FU)/folinic acid (FA) as first-line treatment for metastatic colorectal cancer.

| 2036178 | ecrin-mdr-crc

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

Project description:To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment

| 2008963 | ecrin-mdr-crc

FA Sequencing

Project description:Sequencing FA

| PRJEB5467 | ENA

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Project description:The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.

| 2008962 | ecrin-mdr-crc

FA Sequencing 5Mar2014

Project description:Sequencing FA

| PRJEB5762 | ENA